SCHEMBL7131237

SCHEMBL7131237

N=C(N)NCCC[C@H](NNS(=O)(=O)c1cc(Cl)ccc1Cl)C(=O)N[C@@H](Cc1ccccc1)C(N)=O

nearest known ligand 0.47

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
PSMB5 P28074 1/20 0.47
NPY4R P50391 14/20 0.45
NPY5R Q15761 8/20 0.45
NPY1R P25929 8/20 0.45
NPY2R P49146 5/20 0.45
MMP1 P03956 1/20 0.41
MMP2 P08253 1/20 0.41
MMP9 P14780 1/20 0.41
MMP8 P22894 1/20 0.41
KISS1R Q969F8 2/20 0.41
HTT P42858 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7132417 0.93 NPY4R (0.45) NPY4RNPY5RNPY1RNPY2RKISS1R
SCHEMBL7117913 0.88 NPY4R (0.46) NPY4RNPY5RNPY1RNPY2RMMP2
SCHEMBL7117572 0.87 NPY4R (0.44) NPY4RNPY5RNPY1RNPY2RKISS1R
SCHEMBL7122316 0.86 NPY4R (0.46) NPY4RNPY5RNPY1RNPY2RKISS1R
SCHEMBL7116695 0.85 NPY4R (0.44) NPY4RNPY5RNPY1RNPY2RKISS1R
SCHEMBL7116210 0.85 NPY4R (0.49) NPY4RNPY5RNPY1RNPY2RKISS1R
SCHEMBL7122955 0.84 NPY4R (0.46) NPY4RNPY5RNPY1RNPY2RKISS1R
SCHEMBL7117030 0.84 KCNA5 (0.49) NPY4RNPY5RNPY1RNPY2RKISS1R
SCHEMBL7115442 0.83 BCL2 (0.44) NPY4RNPY5RNPY1RNPY2R
SCHEMBL7123412 0.82 NPY4R (0.44) NPY4RNPY5RNPY1RNPY2RKISS1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030176314-A1 Compounds for the treatment of pain H. LUNDBECK A/S (DK) 2003-09-18 US disclosed
US-20030144310-A1 Molecules specific for NPFF receptors and uses thereof H. LUNDBECK A/S (DK) 2003-07-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030176314-A1 Compounds for the treatment of pain NPFFR2, NPFFR1, OPRL1 PSMB5 2736/4885NPY4R 137/4885NPY5R 159/4885
US-20030144310-A1 Molecules specific for NPFF receptors and uses thereof NPFFR1, NPFFR2, NPBWR1 PSMB5 2314/4885NPY4R 240/4885NPY5R 372/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.